Home > Companies > Dart NeuroScience LLC

Dart NeuroScience LLC

dartneuroscience.com

Dart NeuroScience LLC (DNS) is a privately held company with offices in San Diego, CA. DNS is discovering new technologies and developing new therapies to help maintain cognitive vitality throughout life. DNS's mission is to become the leading specialized pharmaceutical company for memory disorders by focusing on the discovery and development of innovative drugs with new mechanisms of action. These discoveries are firmly based in a careful examination of the genes involved in the reorganization of synaptic connections in the brain, a cellular/molecular process which underlies both implicit (motor skills) and explicit (facts and events) forms of memory.

C-Suite On Deck

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Events

2024 AAPS NATIONAL BIOTECHNOLOGY CONFERENCE

Conference

National Medtech & Biotech Summit 2024

Conference

Related News

Business Insights

ANKURA LAUNCHES PHARMACEUTICAL DATA INTEGRITY SOLUTION

Ankura | March 09, 2022

Ankura Consulting, LLC a leading global expert services and advisory firm announced the expansion of its Pharmaceutical and Biopharma Regulatory Compliance offering with the addition of a Pharmaceutical Data Integrity solution within the Data and Technology practice, bolstering its comprehensive client advisory capabilities. With this solution, Ankura has enhanced its team of experts to support pharmaceutical clients' compliance with the Data Integrity guidelines of multiple r...

Business Insights

XERIS BIOPHARMA ENTERS INTO AGREEMENT FOR $30 MILLION PRIVATE PLACEMENT

Xeris Biopharma Holdings | January 04, 2022

Xeris Biopharma Holdings, Inc. a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology, today announced that on January 2, 2022, it entered into a securities purchase agreement in connection with a private placement with an affiliate of Armistice Capital, LLC for aggregate gross proceeds of approximately $30.0 million. The Private Placement is expected to close on or around January 3, 2022.
Read More

Business Insights, VIEWS AND ANALYSIS

MIRION TECHNOLOGIES TO DIVEST BIODEX PHYSICAL MEDICINE

Biodex Medical Systems | November 30, 2022

Mirion Technologies, Inc. announced that it has entered into a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. to Salona Global Medical Device Corporation for $5 million in cash at closing and up to an additional $3 million in deferred cash payments. The deferred cash payments are contingent on the performance of the assets during the 12-month period following closing. The assets generated approximately $18 million in revenue with estimated gross margins...

PHARMACY MARKET

TRIS PHARMA SECURES FIRST EX-US AUTHORIZATIONS FOR QUILLIVANT ER ORAL SUSPENSION AND QUILLIVANT ER CHEWABLE TABLET FOR THE TREATMENT

Business Wire | September 26, 2023

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain, addiction and neurological disorders, today announced that Health Canada has authorized the use of Quillivant® ER (extended release) for the treatment of attention deficit hyperactivity disorder (ADHD) in children ages 6 to 12. Quillivant ER will be available as both an oral suspension and chewab...

Business Insights